查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1766158

嗜酸性粒细胞药物市场预测（至 2032 年）：按药物类别、疾病类型、给药途径、分销管道、最终用户和地区进行的全球分析

Eosinophilia Therapeutics Market Forecasts to 2032 - Global Analysis By Drug Class, Disease Type, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球嗜酸性粒细胞治疗药物市场预计在 2025 年达到 4.543 亿美元，到 2032 年将达到 7.247 亿美元，预测期内的复合年增长率为 6.9%。

嗜酸性粒细胞药物包括用于控制由过敏性疾病、寄生虫感染疾病以及某些疾病（例如嗜酸性细胞增多症(HES) 和嗜酸性粒细胞气喘）引起的嗜酸性粒嗜酸性粒细胞水平升高的治疗。治疗方法包括皮质类固醇、免疫抑制剂以及标靶生技药品，例如抗 IL-5、抗 IL-4Ra 和抗 IgE 单株抗体。这些疗法旨在透过调节潜在的免疫反应来减少嗜酸性粒细胞发炎、预防器官损伤并改善患者预后。

根据欧洲药品管理局（EMA）的数据，嗜酸性粒细胞增多症（HES）的盛行率为每十万人1.5人。

嗜酸性粒细胞增多症盛行率不断上升

嗜酸性粒细胞增多症盛行率的上升是主要驱动因素。这一增长归因于诊断能力的提高，使得罕见嗜酸性粒细胞症相关疾病能够早期发现，以及导致过敏性和发炎性疾病的环境因素增加。医疗保健专业人员临床意识的提高，提高了对嗜酸性粒细胞细胞性气喘、嗜酸性粒细胞细胞增多症候群和嗜伊红性食道炎的认识。患者群体的不断扩大带来了对标靶治疗的巨大需求，促使製药公司大力投资研发针对这些复杂免疫疾病的专门治疗方法。

新药高成本

儘管单株抗体和标靶生技药品有效，但其高昂的价格限制了患者在整个医疗保健系统中的可及性和采用率。这些治疗方法的特殊性需要大量的临床试验和核准流程，导致高昂的开发成本最终转嫁给消费者。保险覆盖范围的限制和报销挑战进一步限制了市场渗透，尤其是在医疗预算有限的新兴国家，从而导致不同患者群体在治疗可及性方面存在差异。

下一代生技药品和精准医疗的开发

精准医疗方法的进展以及针对IL-5、IL-4和IL-13等特定路径的创新生技药品展现出巨大的市场潜力。针对嗜酸性粒细胞的新型疗法的临床试验正在进行中，这拓展了传统皮质类固醇以外的治疗选择。此外，个人化医疗策略能够根据患者个别情况制定个人化治疗方案，从而改善治疗效果并减少副作用。对嗜酸性粒细胞疾病机制的深入了解将推动更具针对性的疗法的开发，为製药公司提供透过差异化产品满足未满足的医疗需求来抢占市场占有率的机会。

生物相似药的兴起

随着原厂单株抗体专利到期，生物相似药製造商能够提供更具成本效益的替代品，这可能会削弱原厂公司的市场占有率。此外，随着监管机构简化生物相似药的核准途径，生物相似药正加速进入市场，增加了创新药公司的竞争压力。这种威胁可能导致价格竞争加剧，利润率受到挤压，迫使原厂製造商在日益商品化的治疗环境中展示卓越的临床价值或开发下一代疗法。

COVID-19的影响

COVID-19 疫情导致诊断延迟和常规医疗护理推迟，对嗜酸性粒细胞药物市场产生了重大影响。由于医疗系统优先应对疫情，嗜酸性粒细胞细胞增多症的筛检减少，影响了医疗的连续性。然而，这场危机加速了远端医疗和数位健康整合的普及，创造了新的病人参与管道。此外，疫情期间人们对呼吸系统疾病的关注度不断提高，也提高了人们对嗜酸性粒细胞气喘的认识，随着医疗服务恢復正常化，这可能会推动未来市场的成长。

预测期内，皮质类固醇市场预计将实现最大幅度成长

预计皮质类固醇药物将在预测期内占据最大的市场份额，这得益于其在快速控制发炎方面已被证实的有效性，以及其作为各种嗜酸性粒细胞增多症的一线市场占有率的成熟地位。这些药物广泛适用于过敏性、自体免疫和特发性嗜酸性粒细胞增多症，可快速缓解症状，并可在门诊使用。与新型生物製药相比，皮质类固醇药物的成本效益更高，因此受到临床医生的青睐，尤其是在资源匮乏的医疗环境中，从而确保了其在市场上的持续领先地位。

预计在预测期内，网上药局领域将以最高的复合年增长率成长。

在预测期内，由于数位医疗的广泛应用以及越来越多的患者偏好便捷的药品获取方式，预计线上药局领域将呈现最高成长率。数位平台提供增强的患者教育资源、对药物依从性的支持以及简化的处方管理系统，从而改善治疗效果。此外，新冠疫情加速了电子商务在医疗保健领域的应用，使线上药局成为传统零售通路的可行替代方案。此外，这些平台通常提供具有竞争力的价格、宅配服务以及针对慢性病的专业支持，这对于需要长期治疗管理和定期药物补充的嗜酸性粒细胞患者尤其具有吸引力。

比最大的地区

在预测期内，北美预计将占据最大的市场占有率，这得益于其先进的医疗基础设施和基于循证医学的嗜酸性粒细胞增多症药物疗法的广泛采用。该地区受益于专注于免疫疗法的大型生物製药公司的强大影响力、健全的法律规范以及支持生物疗法的全面保险覆盖。此外，医疗保健专业人员临床意识的不断提高和诊断能力的提升，使得该地区能够及早发现并有效管理嗜酸性粒细胞细胞增多症。

复合年增长率最高的地区

在预测期内，北美预计将占据最大的市场占有率，这得益于全部区域医疗基础设施的不断扩大以及人们对过敏和免疫疾病认识的不断提高。中国、印度和日本等国家由于嗜酸性粒细胞增多症盛行率的上升、诊断能力的提高以及医疗保健支出的不断增长，是极具潜力的市场。此外，生技药品和皮质类固醇替代药物的可近性不断提高，以及医生对嗜酸性粒细胞细胞增多症相关知识的不断普及，正在推动市场的强劲扩张。此外，政府的医疗政策也创造了有利条件，使亚太地区成为成长最快的地区。

免费客製化服务

订阅此报告的客户可以选择以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球嗜酸性粒细胞药物市场（依药物类别）

  • 皮质类固醇
  • 单株抗体（生技药品）
    • 抗IL-5/IL-5Ra
    • 抗IL-4Ra
    • 抗IgE
    • 其他的
  • 免疫抑制剂
    • 羟基尿素
    • 干扰素-α
    • Imatinib
  • 质子帮浦抑制剂（PPI）
  • 其他的

6. 全球嗜酸性粒细胞治疗市场（依疾病类型）

  • 嗜酸性粒细胞症（HES）
  • 嗜伊红性食道炎（EoE）
  • 嗜酸性粒细胞气喘
  • 嗜酸性粒细胞肉芽肿性多血管炎（EGPA）
  • 其他的

7. 全球嗜酸性粒细胞药物市场（依给药途径）

  • 口服
  • 肠外（注射）
  • 吸入
  • 局部的

8. 全球嗜酸性粒细胞药物市场（依分销管道）

  • 医院药房
  • 零售药局
  • 网路药局
  • 直销

9. 全球嗜酸性粒细胞治疗市场（依最终用户）

  • 医院
  • 专科诊所
  • 居家照护环境
  • 其他的

第 10 章全球嗜酸性粒细胞治疗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Allakos, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb
  • Cipla Inc.
  • Eli Lilly & Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc（GSK）
  • Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Ltd.
  • Arena Pharmaceuticals Ltd.
  • Ellodi Pharmaceuticals
  • Revolo Biotherapeutics
Product Code: SMRC30014

According to Stratistics MRC, the Global Eosinophilia Therapeutics Market is accounted for $454.3 million in 2025 and is expected to reach $724.7 million by 2032 growing at a CAGR of 6.9% during the forecast period. Eosinophilia therapeutics encompass a range of treatments designed to manage elevated eosinophil levels, which can result from allergic conditions, parasitic infections, or specific disorders like hypereosinophilic syndrome (HES) and eosinophilic asthma. Therapies include corticosteroids, immunosuppressants, and targeted biologics such as anti-IL-5, anti-IL-4Ra, and anti-IgE monoclonal antibodies. These therapeutics aim to reduce eosinophilic inflammation, prevent organ damage, and improve patient outcomes by modulating the underlying immune response.

According to the European Medicines Agency (EMA), the estimated prevalence of hypereosinophilic syndrome (HES) is 1.5 per 100,000 people.

Market Dynamics:

Driver:

Increasing prevalence of eosinophilic disorders

The rising incidence of eosinophilic disorders serves as a primary growth driver. This increase stems from enhanced diagnostic capabilities that enable earlier detection of rare eosinophilia-related conditions, coupled with growing environmental factors contributing to allergic and inflammatory diseases. Heightened clinical awareness among healthcare professionals has led to improved recognition of eosinophilic asthma, hypereosinophilic syndrome, and eosinophilic esophagitis. The expanding patient population creates substantial demand for targeted treatments, driving pharmaceutical companies to invest heavily in research and development of specialized therapies to address these complex immunological conditions.

Restraint:

High cost of novel therapies

Monoclonal antibodies and targeted biologics, while highly effective, command premium pricing that limits patient accessibility and healthcare system adoption. The specialized nature of these therapies requires extensive clinical trials and regulatory approval processes, contributing to elevated development costs that are ultimately passed to consumers. Insurance coverage limitations and reimbursement challenges further restrict market penetration, particularly in emerging economies where healthcare budgets are constrained, creating disparities in treatment access across different patient populations.

Opportunity:

Development of next-generation biologics and precision medicine

The advancement of precision medicine approaches and innovative biologics targeting specific pathways like IL-5, IL-4, and IL-13 represents tremendous market potential. Ongoing clinical trials of novel eosinophil-targeting therapeutic agents are expanding treatment options beyond traditional corticosteroids. Moreover, personalized medicine strategies enable tailored treatment protocols based on individual patient profiles, improving therapeutic outcomes while reducing adverse effects. The growing understanding of eosinophilic disease mechanisms facilitates the development of more targeted interventions, creating opportunities for pharmaceutical companies to capture market share through differentiated products that address unmet medical needs.

Threat:

Emergence of biosimilars

As patents for original monoclonal antibodies expire, biosimilar manufacturers can offer cost-effective alternatives that potentially erode the market share of branded products. Furthermore, regulatory agencies are streamlining approval pathways for biosimilars, accelerating their market entry and increasing competitive pressure on innovator companies. This threat intensifies price competition and may compress profit margins, forcing original manufacturers to demonstrate superior clinical value or develop next-generation therapies in an increasingly commoditized therapeutic environment.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the eosinophilia therapeutics market through delayed diagnoses and postponed routine medical consultations. Healthcare systems prioritized pandemic response, leading to reduced screening for eosinophilic disorders and interrupted treatment continuity. However, the crisis accelerated telemedicine adoption and digital health integration, creating new patient engagement channels. Additionally, heightened focus on respiratory conditions during the pandemic increased awareness of eosinophilic asthma, potentially driving future market growth as healthcare services normalize.

The corticosteroids segment is expected to be the largest during the forecast period

The corticosteroids segment is expected to account for the largest market share during the forecast period due to their proven effectiveness in rapidly controlling inflammation and their established role as first-line therapy for various eosinophilic conditions. These medications offer broad applicability across allergic, autoimmune, and idiopathic eosinophilic disorders while providing fast symptom relief and accessibility in outpatient settings. Their cost-effectiveness compared to newer biologics makes them preferred choices among clinicians, particularly in resource-constrained healthcare environments, ensuring their sustained market leadership.

The online pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the online pharmacies segment is predicted to witness the highest growth rate, driven by increasing digital healthcare adoption and patient preference for convenient medication access. Digital platforms offer enhanced patient education resources, medication adherence support, and streamlined prescription management systems that improve treatment outcomes. Moreover, the COVID-19 pandemic accelerated e-commerce adoption in healthcare, establishing online pharmacies as viable alternatives to traditional retail channels. Additionally, these platforms often provide competitive pricing, home delivery services, and specialized support for chronic conditions, making them particularly attractive for eosinophilia patients requiring long-term therapeutic management and regular medication refills.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to its advanced healthcare infrastructure and high adoption rates of evidence-based pharmacological therapies for eosinophilic disorders. The region benefits from the strong presence of key biopharmaceutical companies specializing in immunological treatments, robust regulatory frameworks, and comprehensive insurance coverage supporting biologic therapies. Furthermore, heightened clinical awareness among healthcare professionals and superior diagnostic capabilities enable early detection and effective management of eosinophil-associated diseases in the region.

Region with highest CAGR:

During the forecast period, the North America region is expected to hold the largest market share due to expanding healthcare infrastructure and increasing awareness of allergic and immunological disorders across the region. Countries like China, India, and Japan represent high-potential markets due to the growing prevalence of eosinophilic diseases, improved diagnostic capabilities, and rising healthcare expenditure. Additionally, enhanced access to biologics and corticosteroid alternatives, combined with growing physician education on eosinophilic disorders, drives strong market expansion. Moreover, government healthcare policies create favorable conditions, positioning Asia Pacific as the fastest growing region.

Key players in the market

Some of the key players in Eosinophilia Therapeutics Market include Allakos, Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, Cipla Inc., Eli Lilly & Company, Gilead Sciences, Inc., GlaxoSmithKline plc (GSK), Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Takeda Pharmaceutical Company Ltd., Arena Pharmaceuticals Ltd., Ellodi Pharmaceuticals, and Revolo Biotherapeutics.

Key Developments:

In May 2025, GSK plc announced that the US Food and Drug Administration (FDA) have approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype. FDA's approval was based on data from the positive MATINEE and METREX phase III trials. Across these trials, mepolizumab showed a clinically meaningful and statistically significant reduction in the annualised rate of moderate/severe exacerbations versus placebo in a wide spectrum of COPD patients with an eosinophilic phenotype.

In May 2025, AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Francisco, CA from 16 to 21 May 2025. With more than 75 abstracts, including eight late-breakers, the Company continues to drive innovation and address unmet needs in care across all severities of asthma, chronic obstructive pulmonary disease (COPD), eosinophilic granulomatosis with polyangiitis (EGPA) and other chronic inflammatory diseases.

In February 2024, Takeda announced that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE).1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.

Drug Classes Covered:

  • Corticosteroids
  • Monoclonal Antibodies (Biologics)
  • Immunosuppressants
  • Proton Pump Inhibitors (PPIs)
  • Other Drug Classes

Disease Types:

  • Hypereosinophilic Syndrome (HES)
  • Eosinophilic Esophagitis (EoE)
  • Eosinophilic Asthma
  • Eosinophilic Granulomatosis with Polyangiitis (EGPA)
  • Other Eosinophilic Disorders

Route of Administrations:

  • Oral
  • Parenteral (Injectable)
  • Inhalation
  • Topical

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Direct Distribution

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Other Healthcare Facilities

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Eosinophilia Therapeutics Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Corticosteroids
  • 5.3 Monoclonal Antibodies (Biologics)
    • 5.3.1 Anti-IL-5/IL-5Ra
    • 5.3.2 Anti-IL-4Ra
    • 5.3.3 Anti-IgE
    • 5.3.4 Other Emerging Biologics
  • 5.4 Immunosuppressants
    • 5.4.1 Hydroxyurea
    • 5.4.2 Interferon-a
    • 5.4.3 Imatinib
  • 5.5 Proton Pump Inhibitors (PPIs)
  • 5.6 Other Drug Classes

6 Global Eosinophilia Therapeutics Market, By Disease Type

  • 6.1 Introduction
  • 6.2 Hypereosinophilic Syndrome (HES)
  • 6.3 Eosinophilic Esophagitis (EoE)
  • 6.4 Eosinophilic Asthma
  • 6.5 Eosinophilic Granulomatosis with Polyangiitis (EGPA)
  • 6.6 Other Eosinophilic Disorders

7 Global Eosinophilia Therapeutics Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Parenteral (Injectable)
  • 7.4 Inhalation
  • 7.5 Topical

8 Global Eosinophilia Therapeutics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Direct Distribution

9 Global Eosinophilia Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Specialty Clinics
  • 9.4 Homecare Settings
  • 9.5 Other Healthcare Facilities

10 Global Eosinophilia Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Allakos, Inc.
  • 12.2 AstraZeneca plc
  • 12.3 Bayer AG
  • 12.4 Bristol-Myers Squibb
  • 12.5 Cipla Inc.
  • 12.6 Eli Lilly & Company
  • 12.7 Gilead Sciences, Inc.
  • 12.8 GlaxoSmithKline plc (GSK)
  • 12.9 Hoffmann-La Roche Ltd.
  • 12.10 Merck & Co., Inc.
  • 12.11 Novartis AG
  • 12.12 Pfizer Inc.
  • 12.13 Regeneron Pharmaceuticals, Inc.
  • 12.14 Sanofi S.A.
  • 12.15 Takeda Pharmaceutical Company Ltd.
  • 12.16 Arena Pharmaceuticals Ltd.
  • 12.17 Ellodi Pharmaceuticals
  • 12.18 Revolo Biotherapeutics

List of Tables

  • Table 1 Global Eosinophilia Therapeutics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Eosinophilia Therapeutics Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 3 Global Eosinophilia Therapeutics Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 4 Global Eosinophilia Therapeutics Market Outlook, By Monoclonal Antibodies (Biologics) (2024-2032) ($MN)
  • Table 5 Global Eosinophilia Therapeutics Market Outlook, By Anti-IL-5/IL-5Ra (2024-2032) ($MN)
  • Table 6 Global Eosinophilia Therapeutics Market Outlook, By Anti-IL-4Ra (2024-2032) ($MN)
  • Table 7 Global Eosinophilia Therapeutics Market Outlook, By Anti-IgE (2024-2032) ($MN)
  • Table 8 Global Eosinophilia Therapeutics Market Outlook, By Other Emerging Biologics (2024-2032) ($MN)
  • Table 9 Global Eosinophilia Therapeutics Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 10 Global Eosinophilia Therapeutics Market Outlook, By Hydroxyurea (2024-2032) ($MN)
  • Table 11 Global Eosinophilia Therapeutics Market Outlook, By Interferon-a (2024-2032) ($MN)
  • Table 12 Global Eosinophilia Therapeutics Market Outlook, By Imatinib (2024-2032) ($MN)
  • Table 13 Global Eosinophilia Therapeutics Market Outlook, By Proton Pump Inhibitors (PPIs) (2024-2032) ($MN)
  • Table 14 Global Eosinophilia Therapeutics Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 15 Global Eosinophilia Therapeutics Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 16 Global Eosinophilia Therapeutics Market Outlook, By Hypereosinophilic Syndrome (HES) (2024-2032) ($MN)
  • Table 17 Global Eosinophilia Therapeutics Market Outlook, By Eosinophilic Esophagitis (EoE) (2024-2032) ($MN)
  • Table 18 Global Eosinophilia Therapeutics Market Outlook, By Eosinophilic Asthma (2024-2032) ($MN)
  • Table 19 Global Eosinophilia Therapeutics Market Outlook, By Eosinophilic Granulomatosis with Polyangiitis (EGPA) (2024-2032) ($MN)
  • Table 20 Global Eosinophilia Therapeutics Market Outlook, By Other Eosinophilic Disorders (2024-2032) ($MN)
  • Table 21 Global Eosinophilia Therapeutics Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 22 Global Eosinophilia Therapeutics Market Outlook, By Oral (2024-2032) ($MN)
  • Table 23 Global Eosinophilia Therapeutics Market Outlook, By Parenteral (Injectable) (2024-2032) ($MN)
  • Table 24 Global Eosinophilia Therapeutics Market Outlook, By Inhalation (2024-2032) ($MN)
  • Table 25 Global Eosinophilia Therapeutics Market Outlook, By Topical (2024-2032) ($MN)
  • Table 26 Global Eosinophilia Therapeutics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 27 Global Eosinophilia Therapeutics Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 28 Global Eosinophilia Therapeutics Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 29 Global Eosinophilia Therapeutics Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 30 Global Eosinophilia Therapeutics Market Outlook, By Direct Distribution (2024-2032) ($MN)
  • Table 31 Global Eosinophilia Therapeutics Market Outlook, By End User (2024-2032) ($MN)
  • Table 32 Global Eosinophilia Therapeutics Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 33 Global Eosinophilia Therapeutics Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 34 Global Eosinophilia Therapeutics Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 35 Global Eosinophilia Therapeutics Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.